Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-07-10 16:17:38 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
AS Desai, AD Karns, J Badariene, A Aswad, JM Neutel…
JAMA, 2025
jamanetwork.com
Importance In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months. Objective To evaluate the efficacy and safety of zilebesiran vs placebo when added to a standard antihypertensive medication. Design, Setting, and Participants This phase 2, randomized, prospective, double-blinded trial enrolled adults with uncontrolled hypertension from 150 …
